Publications

Media

Publications

15 November 2016

A unique type of GSK-3 inhibitor brings new opportunities to the clinic

Avital Licht-Murava, Rom Paz, Lilach Vaks, Limor Avrahami, Batya Plotkin, Miriam Eisenstein, Hagit Eldar-Finkelman

Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3

Ele ́onore Beurel,* Oksana Kaidanovich-Beilin,† Wen-I Yeh,‡ Ling Song,* Valle Palomo,x Suzanne M. Michalek,{ James R. Woodgett,†,‖ Laurie E. Harrington,‡ Hagit Eldar-Finkelman,# Ana Martinez,x and Richard S. Jope*

GSK-3 inhibition: Achieving moderate efficacy with high selectivity

Limor Avrahami a , Avital Licht-Murava a , Miriam Eisenstein b , Hagit Eldar-Finkelman a,

GSK-3 inhibitors: preclinical and clinical focus on CNS

Hagit Eldar-Finkelman1* and Ana Martinez2*

Substrate Competitive GSK-3 Inhibitors \ strategy and Implications

Hagit Eldar-Finkelman a, ⁎, Avital Licht-Murava a , Shmuel Pietrokovski b , Miriam Eisenstein c

Peptide Inhibitors Targeting Protein Kinases

Hagit Eldar-Finkelman1,* and Miriam Eisenstein2,*

Role of glycogen synthase kinase-3β in early depressive behavior induced by mild traumatic brain injury

Moran Shapira,a Avital Licht,a Anat Milman,b Chaim G. Pick,b Esther Shohami,c and Hagit Eldar-Finkelmana,⁎

Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3

BATYA PLOTKIN, OKSANA KAIDANOVICH, ILANA TALIOR, and HAGIT ELDAR-FINKELMAN

Rapid Antidepressive-Like Activity of Specific Glycogen Synthase Kinase-3 Inhibitor and Its Effect on -Catenin in Mouse Hippocampus

Oksana Kaidanovich-Beilin, Anat Milman, Abraham Weizman, Chaim G. Pick, and Hagit Eldar-Finkelman